Skip to main content

Advertisement

Table 3 Cox models for DFS and OS (univariate analysis)

From: Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy

  Univariate analysis - DFS Univariate analysis - OS
Variable HR 95% CI p HR 95% CI p
Age (per years) 1.01 0.99 1.04 0.270 1.05 1.01 1.08 0.005
ER- PgR- 1 (reference) 1 (reference)
ER+ PgR- / ER- PgR+ 0.72 0.40 1.30 0.273 0.64 0.30 1.40 0.269
ER+ PgR+ 0.51 0.29 0.89 0.018 0.51 0.25 1.04 0.066
Stage I 1 (reference) 1 (reference)
Stage II 2.01 1.13 3.56 0.018 3.73 1.48 9.41 0.005
Stage III 3.77 2.01 7.08 <0.001 9.77 3.85 24.82 <0.001
LN (pos vs. neg) 1.79 1.11 2.88 0.016 2.61 1.37 4.98 0.004
HER2 (pos vs. neg) 1.51 0.75 3.04 0.251 1.67 0.70 3.97 0.248
GSTT1 (null vs. present) 1.68 0.99 2.86 0.053 2.22 1.17 4.24 0.015
GSTM1 (present vs. null) 1.23 0.77 1.98 0.383 1.68 0.90 3.12 0.103
RFC1 – AA 1 (reference) 1 (reference)
RFC1 – GA 2.35 1.09 5.07 0.029 1.95 0.73 5.22 0.184
RFC1 – GG 2.89 1.31 6.38 0.009 2.90 1.07 7.88 0.036
GSTP1 – AA 1 (reference) 1 (reference)
GSTP1 – AG 0.77 0.46 1.26 0.297 - - - 0.989
GSTP1 – GG - - - 0.985 0.80 0.42 1.53 0.500
MTHFR – CC 1 (reference) 1 (reference)
MTHFR – CT 1.28 0.72 2.27 0.394 1.02 0.49 2.13 0.957
MTHFR – TT 0.85 0.42 1.71 0.642 0.96 0.41 2.25 0.920
TS-TR – 2R/2R 1 (reference) 1 (reference)
TS-TR – 2R/3R 0.62 0.35 1.11 0.105 0.67 0.31 1.48 0.327
TS-TR – 3R/3R 0.80 0.46 1.41 0.439 1.11 0.54 2.28 0.767
Combined genotype groups*   
Group 1 1 (reference) 1 (reference)
Group 2 4.20 1.52 11.56 0.006 4.54 1.09 18.92 0.038
Group 3 6.61 1.93 22.59 0.003 10.12 2.04 50.19 0.005
  1. HR Hazard Ratio, CI Confidence Interval, DFS Disease free Survival, OS Overall Survival, LN lymph nodes
  2. *group1: GSTT1-present and RFC1-AA
  3. group2: GSTT1-present and RFC1-GA/RFC1-GG or GSTT1-null and RFC1-GA/RFC1-AA
  4. group3: GSTT1-null and RFC1-GG